Elite in Pulmonary Fibrosis

Carlo Vancheri

Ct, 
Catania, IT 
Elite in Pulmonary Fibrosis
Ct, 
Catania, IT 
OverviewLocationsClinical Research

Overview

Carlo Vancheri practices in Catania, Italy. Mr. Vancheri is rated as an Elite expert by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Lung Transplant.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 106 articles and participated in 2 clinical trials in the study of Pulmonary Fibrosis.

Gender
Male

Locations

Ct, Catania, 95123, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
View 1 Less Clinical Trial

185 Total Publications

Vascular protection by young circulating extracellular vesicles ameliorates aging-related pulmonary fibrosis.
Vascular protection by young circulating extracellular vesicles ameliorates aging-related pulmonary fibrosis.
Journal: American journal of physiology. Cell physiology
Published: May 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vancheri's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile